GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-448-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$70.76 million
Profitability
Miscellaneous
Employees517
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings data on Thursday, February, 21st. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.05. The medical equipment provider earned $19.38 million during the quarter, compared to the consensus estimate of $19.22 million. GenMark Diagnostics had a negative return on equity of 98.45% and a negative net margin of 71.37%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What guidance has GenMark Diagnostics issued on next quarter's earnings?
GenMark Diagnostics issued an update on its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $85-90 million, compared to the consensus revenue estimate of $86.66 million.
What price target have analysts set for GNMK?
5 analysts have issued 12-month price targets for GenMark Diagnostics' shares. Their forecasts range from $7.00 to $12.00. On average, they expect GenMark Diagnostics' stock price to reach $9.75 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.
What is the consensus analysts' recommendation for GenMark Diagnostics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.
What are Wall Street analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. Needham & Company LLC analysts commented, "GNMK’s 4Q18 revenue was consistent with its preannouncement while its EPS missed consensus. Management provided 2019 revenue guidance that was above consensus at the mid-point and ePlex placement guidance that was above our estimate at the mid-point. GNMK placed 42 ePlex systems in 4Q18, down from 45 in 3Q18 but above our estimate of 39. We believe the 4Q18 results provide further evidence that ePlex is gaining momentum while GNMK works out its manufacturing growing pains. We think an expanding test menu should help drive ePlex placements and utilization 2019 and we reiterate our Buy rating." (2/22/2019)
- 2. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (2/12/2019)
Has GenMark Diagnostics been receiving favorable news coverage?
Headlines about GNMK stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GenMark Diagnostics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Atrion (ATRI), Nevro (NVRO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), Luminex (LMNX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR) and Axonics Modulation Technologies (AXNX).
What other stocks do shareholders of GenMark Diagnostics own?
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- Mr. Hany Massarany, CEO, Pres & Director (Age 58)
- Mr. Scott Mendel, Chief Financial Officer (Age 52)
- Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
- Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 54)
- Mr. Johnny Ek, VP of Fin. & Accounting and Corp. Controller
Who are GenMark Diagnostics' major shareholders?
GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Casdin Capital LLC (6.82%), BlackRock Inc. (6.50%), Bellevue Group AG (3.57%), Bank of America Corp DE (2.15%), Penn Capital Management Co. Inc. (1.43%) and Northern Trust Corp (1.23%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
Which major investors are selling GenMark Diagnostics stock?
GNMK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Thrivent Financial for Lutherans, TD Asset Management Inc., Donaldson Capital Management LLC, MetLife Investment Advisors LLC, Royce & Associates LP, Two Sigma Advisers LP and Stephens Inc. AR. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.
Which major investors are buying GenMark Diagnostics stock?
GNMK stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Assenagon Asset Management S.A., Penn Capital Management Co. Inc., Casdin Capital LLC, Bank of America Corp DE, Rhumbline Advisers, Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for GenMark Diagnostics.
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $7.31.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $409.07 million and generates $70.76 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.
What is GenMark Diagnostics' official website?
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
